HOME >> MEDICINE >> NEWS
Is Ritalin As Effective--And As Harmless--As It Could Be?

DALLAS, March 29 -- Ritalin, the treatment of choice for an estimated 2 million or more children suffering from attention deficit hyperactivity disorder, could be more effective and cause fewer side-effects if it were administered as a single compound rather than as a mixture, say chemists at Brookhaven National Laboratory. Yu-Shin Ding, Ph.D., and colleagues presented their findings here today at the national meeting of the American Chemical Society, world's largest scientific society.

Methylphenidate (marketed as Ritalin) is a chiral drug, meaning that it comes in two molecular forms, one a mirror image of the other (enantiomers). Currently Ritalin, which topped $350 million in sales last year, said Ding, is distributed as a "racemic" mixture of both its chiral molecules -- d-threo and l-threo.

However, some evidence has suggested that the drug's therapeutic effect resides solely in the d-threo enantiomer, which is about 10 times more potent than its chiral counterpart, according to Ding. "If the beneficial effects of the drug reside only in the d-threo form," she said, "then fifty percent of the weight of the administered drug may not contribute to its therapeutic effects."

Ding, along with colleagues Joanna S. Fowler and Nora Volkow, studied the individual effects of d-threo and l-threo on the central nervous system. They tagged each enantiomer with a short-lived radioactive tracer chemical -- calleda carbon-11 isotope -- with a half-life of 20 minutes. They then used positron emission tomography (PET) to compare the enantiomers' effects in the brains of baboons and humans. (Radiotracers emit signals as they decay that can be collected by a PET scan to generate images.) The study showed that the d-threo enantiomer bound precisely to the dopamine targets in the brain, while the binding of l-threo was mostly non-specific.

What's more, Ding says, the l-threo enantiomer may ha
'"/>

Contact: Jim Bohning
j_bohning@acs.org
202/872-6041
American Chemical Society
29-Mar-1998


Page: 1 2

Related medicine news :

1. New studies on Ritalin and Alzheimers Disease highlight ACNP Annual Meeting
2. Study reveals differences in patients response to Ritalin
3. Ritalin helps children with ADHD maintain normal reaction time
4. Ritalin and Prozac: Study finds more kids using both drug types together
5. Boys treated with Ritalin, other stimulants significantly less likely to abuse drugs later
6. First Trial Comparing Adderall To Ritalin For ADHD Shows It To Be Longer-Lasting, Equally As Effective
7. Improved Ritalin Offers Smaller Doses And Fewer Side Effects
8. New Theory May Explain Ritalin Action In Hyperactivity
9. How Ritalin Enhances Memory: Clues Provided By Brain Scans of ADHD Patients Using The Drug
10. Could skin cells become brain cells?
11. Could autoantibodies predict future disease in healthy people?

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Ritalin Effective And Harmless Could

(Date:8/31/2015)... ... August 31, 2015 , ... For 12 years, since ... acknowledged September 26th as Mesothelioma Awareness Day . On this day, and in ... several ways of becoming involved and helping the cause. , “One of the ways ...
(Date:8/31/2015)... ... , ... MeYou Health ®, a social well-being company and wholly owned ... by including an in-app step tracker. , Walkadoo is a pedometer-based walking program ... than broadly assign every Walkadoo member 10,000 steps a day (as is typical for ...
(Date:8/31/2015)... ... ... It’s a lot like coming home. Life-long Fox Valley resident James Holbrook has ... on the job, he’s run into residents of the retirement community who he’s known ... living in such a wonderful place,” he said. GreenFields, which is sponsored by Friendship ...
(Date:8/31/2015)... ... August 31, 2015 , ... PartnerTech hosted ... Owners and provided a tour of their North American facility following the S.M.A.R.T ... international companies expanding business in the U.S. , The PartnerTech Inc. North ...
(Date:8/31/2015)... Dallas, TX (PRWEB) , ... August 31, 2015 ... ... Coalition’s EARLIER Awareness campaign, TAKE ACTION. NOT CHANCES. (SM) will be featured on ... building. The eye-catching campaign image is designed to inspire and promote earlier awareness ...
Breaking Medicine News(10 mins):Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 3Health News:Walkadoo™ Walking Program Now Includes In-app Step Tracker 2Health News:Friendship Senior Options Welcomes New Executive Director for GreenFields of Geneva 2Health News:PartnerTech Supports Economic Growth as Host 2Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 2Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 3
(Date:8/31/2015)... and MOUNTAIN VIEW, Calif. , ... SNY ; EURONEXT: SAN) and the life sciences team ... improve care and outcomes for people with type 1 ... diabetes treatments and devices with Google,s expertise in analytics, ... will explore how to improve diabetes care by developing ...
(Date:8/31/2015)... 31, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... field of regenerative medicine, today announced that the ... Chicago -based Rush University Medical Center in ... escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) in ... cervical spinal cord injury (SCI). This represents the ...
(Date:8/31/2015)... 2015   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... media and a related cloud hosted ... smart shippers ("BioLife" or the "Company"), today ... biopharmaceutical company focused on developing and commercializing novel ...
Breaking Medicine Technology:Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5
Cached News: